ZBH
HealthcareZimmer Biomet Holdings, Inc. · Medical - Devices · $17B
What is Zimmer Biomet Holdings, Inc.?
Zimmer Biomet Holdings is a global musculoskeletal healthcare company headquartered in Warsaw, Indiana, serving surgeons and hospitals across the Americas, Europe, and Asia Pacific.
The company designs, manufactures, and markets orthopaedic reconstructive products — primarily knee and hip implants — alongside sports medicine, spine, dental, and chest reconstruction devices. Revenue flows through sales to orthopedic surgeons, hospitals, and healthcare purchasing organizations worldwide.
Founded in 1927, Zimmer Biomet adopted its current name in June 2015 following the merger with Biomet.
- Knee and hip reconstructive implants
- Sports medicine and extremity products
- Spine and dental reconstructive devices
- Robotic and surgical enabling technologies
Is ZBH a Good Stock to Buy?
UQS Score rates ZBH as Below Average overall.
Valuation stands out as the brightest spot in ZBH's profile, rating Attractive relative to peers — a potential entry-point consideration for patient investors. Quality and Moat both register as Neutral, reflecting a defensible but undifferentiated market position.
Growth and Risk both score Weak, signaling sluggish revenue momentum and meaningful balance-sheet or operational pressures that warrant caution.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ZBH pay dividends?
Yes — Zimmer Biomet Holdings, Inc. pays a dividend.
ZBH pays a regular dividend, which may appeal to income-oriented investors in the healthcare device space. Given the Weak Growth and Risk profile, prospective buyers should weigh dividend sustainability carefully before relying on the payout as a primary return driver.
When does ZBH report earnings?
Zimmer Biomet reports earnings on a quarterly cadence, consistent with US-listed large-cap equities.
The company's Weak Growth pillar suggests recent top-line results have trailed sector peers, with limited near-term acceleration visible in the UQS framework. Operational execution in a competitive orthopaedics market remains a key watchpoint each quarter.
For the most recent quarter's results and guidance, visit Zimmer Biomet's investor relations page directly.
ZBH Price History
-40.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Zimmer Biomet Holdings, Inc.?
Based on Zimmer Biomet Holdings, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Zimmer Biomet do?
Zimmer Biomet designs and sells orthopaedic implants — mainly knees and hips — along with spine, dental, sports medicine, and robotic surgical products. Its customers include orthopedic surgeons, hospitals, and healthcare purchasing organizations across more than 25 countries.
Does ZBH pay dividends?
Yes, Zimmer Biomet pays a regular dividend. Income investors should review the current payout level and the company's cash-flow profile — available in full on the UQS Pro dashboard — before drawing conclusions about sustainability.
When does ZBH report earnings?
ZBH follows a standard quarterly reporting schedule. Our data source does not publish specific upcoming dates, so check Zimmer Biomet's investor relations page for the current earnings calendar.
Is ZBH a good stock to buy?
UQS Score rates ZBH Below Average, driven by Weak Growth and Risk pillars. The Attractive Valuation label may interest contrarian investors, but the overall composite suggests meaningful headwinds. Pro members can view the complete pillar breakdown to form their own view.
Is ZBH overvalued?
The UQS Valuation pillar rates ZBH as Attractive, meaning the stock appears reasonably priced relative to sector peers on the metrics UQS tracks. That said, valuation alone does not offset the Weak Growth and Risk signals in the full composite.
What is ZBH's market cap bracket?
Zimmer Biomet is classified as a large-cap company, placing it among the more established players in the medical device and orthopaedics space.
Is ZBH a long-term quality investment?
As a long-term quality indicator, ZBH's Below Average UQS Score reflects concerns around growth trajectory and risk factors. The Neutral Moat and Quality pillars suggest a defensible but not dominant business. Long-term investors should monitor whether growth and risk trends improve over time.
What sector does ZBH belong to?
Zimmer Biomet operates in the Healthcare sector, specifically within the medical devices and orthopaedic reconstructive products industry. You can explore other [healthcare stocks scored by UQS](/sector/healthcare) for sector-wide comparisons.
Unlock Full ZBH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data
- ✓Compare ZBH head-to-head against orthopaedic and medical device peers
- ✓Get the complete analyst-style breakdown available to Pro members
Pro Analysis
ZBH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 51.7 | 49.2 | 46.0 | 34.4 | 47.9 | 92.0 | 0.0 |
| May 14, 2026 | 51.7 | 49.2 | 46.0 | 34.4 | 47.9 | 92.5 | 0.0 |
| May 12, 2026 | 51.7 | 49.2 | 46.0 | 34.4 | 47.9 | 92.1 | +1.7 |
| May 3, 2026 | 50.0 | 48.3 | 46.0 | 34.5 | 37.5 | 92.9 | +0.1 |
| May 1, 2026 | 49.9 | 48.3 | 46.0 | 34.5 | 37.5 | 91.9 | 0.0 |
| Apr 26, 2026 | 49.9 | 48.3 | 46.0 | 34.6 | 37.5 | 91.9 | 0.0 |
| Apr 19, 2026 | 49.9 | 48.3 | 46.0 | 34.6 | 37.5 | 91.5 | +0.2 |
| Apr 18, 2026 | 49.7 | 48.3 | 46.0 | 34.6 | 37.5 | 90.4 | -0.9 |
| Apr 14, 2026 | 50.6 | 48.3 | 46.0 | 34.6 | 37.5 | 96.3 | -0.1 |
| Apr 12, 2026 | 50.7 | 48.3 | 46.0 | 34.6 | 37.5 | 97.3 | -0.2 |
ZBH — Pillar Breakdown
Quality
— 49.2/100 (25%)Zimmer Biomet Holdings, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 34.4/100 (20%)Zimmer Biomet Holdings, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 47.9/100 (15%)Zimmer Biomet Holdings, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 92.0/100 (15%)Zimmer Biomet Holdings, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Zimmer Biomet Holdings, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ZBH.
Score Composition
Financial Data
More Stock Analysis
How is the ZBH UQS Score Calculated?
The UQS (Unified Quality Score) for Zimmer Biomet Holdings, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Zimmer Biomet Holdings, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Zimmer Biomet Holdings, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.